Compounder Clinical Specialties expands recall, FDA alerts
This article was originally published in Scrip
Executive Summary
Federal regulators on 21 March said a recall of products from a George compounding pharmacy has been expanded to include all of its sterile drugs – going well beyond the lots of compounded forms of Genentech's Avastin (bevacizumab) the agency had alerted the health care community about earlier in the week.